title: Development and validation of a rapid stability indicating HPLC-method using monolithic stationary phase and two spectrophotometric methods for determination of antihistaminic acrivastine in capsules.
abstract: Simple, rapid and accurate high performance liquid chromatographic (HPLC) and spectrophotometric methods are described for determination of antihistaminic acrivastine in capsules. The first method (method A) is based on accurate, sensitive and stability indicating chromatographic separation method. Chromolith® Performance RP-18e column, a relatively new packing material consisting of monolithic rods of highly porous silica, was used as stationary phase applying isocratic binary mobile phase of ACN and 25 mM NaH2PO4 pH 4.0 in the ratio of 22.5:77.5 at flow rate of 5.0 mL/min and 40°C. A diode array detector was used at 254 nm for detection. The elution time of acrivastine was found to be 2.080±0.032. The second and third methods (methods B and C) are based on the oxidation of acrivastine with excess N-bromosuccinimide (NBS) and determination of the unconsumed NBS with, metol-sulphanilic acid (λmax: 520 nm) or amaranth dye (λmax: 530 nm). The reacted oxidant corresponds to the drug content. Beer's law is obeyed over the concentration range 1.563-50, 2.0-20 and 1.0-10 μg mL(-1) for methods A, B and C, respectively. The limits of detection and quantitation were 0.40, 0.292 and 0.113 μg mL(-1) and 0.782, 0.973 and 0.376 μg mL(-1) for methods A, B and C, respectively. The HPLC method was validated for system suitability, linearity, precision, limits of detection and quantitation, specificity, stability and robustness. Stability tests were done through exposure of the analyte solution for four different stress conditions and the results indicate no interference of degradants with HPLC-method. The proposed methods was favorably applied for determination of acrivastine in capsules formulation. Statistical comparison of the obtained results from the analysis of the studied drug to those of the reported method using t- and F-tests showed no significant difference between them.
authors.affiliation: Chemistry Department, Faculty of Science, Zagazig University, Zagazig 44519, Egypt; Faculty of Public Health and Informatics, Umm AL-Qura University, Makkah, Saudi Arabia. Electronic address: aymangouda77@gmail.com.
authors.forename: Ayman A
authors.initials: AA
authors.lastname: Gouda
authors.affiliation: Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Jazan University, Saudi Arabia.
authors.forename: Hisham
authors.initials: H
authors.lastname: Hashem
authors.affiliation: Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry, Ernst-Moritz-Arndt-University Greifswald, F.-L.-Jahn-Str. 17, D-17487 Greifswald, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Jira
mesh_terms: D001974:Bromosuccinimide / Q000737:chemistry; D002138:Calibration; D002214:Capsules; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D002853:Chromatography, Liquid; D006633:Histamine Antagonists / Q000737:chemistry*; D006863:Hydrogen-Ion Concentration; D010100:Oxygen / Q000737:chemistry; D015203:Reproducibility of Results; D013053:Spectrophotometry / Q000379:methods*; D013056:Spectrophotometry, Ultraviolet; D013696:Temperature; D013997:Time Factors; D014311:Triprolidine / Q000031:analogs & derivatives* / Q000737:chemistry
chemical_list: D002214:Capsules; D006633:Histamine Antagonists; D014311:Triprolidine; C043648:acrivastine; D001974:Bromosuccinimide; D010100:Oxygen
keywords: Acrivastine; Capsules; Monolithic columns; N-bromosuccinimide; Spectrophotometry; Stability indicating LC-method